Patents by Inventor Shiro Murata

Shiro Murata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227871
    Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.
    Type: Application
    Filed: January 19, 2022
    Publication date: July 21, 2022
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 11312773
    Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 26, 2022
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 11198730
    Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: December 14, 2021
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Publication number: 20210277124
    Abstract: The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.
    Type: Application
    Filed: August 10, 2017
    Publication date: September 9, 2021
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Publication number: 20210254079
    Abstract: The present invention provides mammalian cell expression vectors that impart to mammalian host cells an ability to produce high levels of foreign gene-derived proteins. A ubiquitously acting chromatin opening element (UCOE) is introduced into an expression vector that has a plasmid DNA integrated into a transcriptional hot spot on the chromosome of a dihydrofolate reductase gene-deficient host cell so that it allows for selection of strains that grow in hypoxanthine-thymidine (hereinafter denoted as HT)-free medium, whereby transformants will produce a protein of interest in increased amounts.
    Type: Application
    Filed: May 12, 2019
    Publication date: August 19, 2021
    Applicants: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Yasuhiko SUZUKI, Miki NAKAGAWA, Yayoi KAMEDA, Satoru KONNAI, Tomohiro OKAGAWA, Naoya MAEKAWA, Shinya GOTO, Yamato SAJIKI, Kazuhiko OHASHI, Shiro MURATA, Yuzuru KITAHARA, Keiichi YAMAMOTO
  • Publication number: 20210079095
    Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 18, 2021
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 10865246
    Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 15, 2020
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
  • Publication number: 20200131270
    Abstract: The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.
    Type: Application
    Filed: July 19, 2018
    Publication date: April 30, 2020
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Satoru KONNAI, Kazuhiko OHASHI, Shiro MURATA, Tomohiro OKAGAWA, Naoya MAEKAWA, Asami NISHIMORI, Shinya GOTO, Yasuhiko SUZUKI, Chie NAKAJIMA, Yamato SAJIKI
  • Publication number: 20200100688
    Abstract: A patient monitor device configured to display vital information of a living body includes: a display; and circuitry configured to individually display at least two types of the vital information of the living body on a plurality of display regions of the display. Each of the display regions includes: a numerical value display portion for displaying measured vital information of the living body as a numerical value; and a tab portion for notifying of completion of the measurement after the measurement of the vital information is completed, and tab portions of respective display regions are arranged in a line along an array of respective numerical value display portions.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 2, 2020
    Inventor: Shiro MURATA
  • Publication number: 20200031932
    Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
    Type: Application
    Filed: March 23, 2018
    Publication date: January 30, 2020
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
  • Publication number: 20190185568
    Abstract: The present invention provides an anti-PD-1 antibody capable of repeated administration even to animals other than rat. An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 18), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 19) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above-described anti-PD-1 antibody as an active ingredient. A method for preparing the anti-PD-1 antibody is also provided.
    Type: Application
    Filed: August 10, 2017
    Publication date: June 20, 2019
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Publication number: 20190169294
    Abstract: The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (h) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.
    Type: Application
    Filed: August 10, 2017
    Publication date: June 6, 2019
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 9762977
    Abstract: A terminal device in which a transmitter transmits biological information and battery state information to a biological information display device, includes a shutdown detector that detects a shutdown state of a battery, and a transmission controller that, when the shutdown detector detects the battery shutdown state, causes the transmitter to transmit the battery state information indicative of shutdown.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 12, 2017
    Assignee: NIHON KOHDEN CORPORATION
    Inventors: Kiyohiro Omori, Takayoshi Okano, Shiro Murata
  • Publication number: 20150271574
    Abstract: A terminal device in which a transmitter transmits biological information and battery state information to a biological information display device, includes a shutdown detector that detects a shutdown state of a battery, and a transmission controller that, when the shutdown detector detects the battery shutdown state, causes the transmitter to transmit the battery state information indicative of shutdown.
    Type: Application
    Filed: March 11, 2015
    Publication date: September 24, 2015
    Inventors: Kiyohiro Omori, Takayoshi Okano, Shiro Murata
  • Publication number: 20020137831
    Abstract: Disclosed is a polymeric PTC composition comprising an organic polymer and conductive particles having a melting point of not less than 2000° C. dispersed therein and a circuit protection device comprising a PTC element comprising the PTC composition which are treated with a coupling agent and at least two electrodes which are electrically connected to the PTC element. The polymeric PTC composition is used to provide a circuit protection device having excellent environmental resistance properties, which exhibits a low resistance under normal operating conditions, and protects the circuit against the over-current even under large electric current and high voltage.
    Type: Application
    Filed: April 20, 2000
    Publication date: September 26, 2002
    Inventors: Hideo Horibe, Itsuo Nishiyama, Osamu Hiroi, Teijiro Mori, Tatsuya Hayashi, Chie Takahashi, Shiro Murata, Kenichi Nishina, Manabu Sogabe, Masahiro Ishikawa
  • Patent number: 6373014
    Abstract: A current limiting device includes first and second contact members, each contact member having, at a first end, contacts defining a contact pair; a contacting pressure is applied to said contact pair; and a cylindrical insulator cylindrically surrounding the contacts when the contacts are closed. The device is arranged such that at least one of the first and second contact members is rotatably supported at a second end. Also, an electrical path is defined through which currents flow in substantial opposition to the first and second contact members and in opposite directions to each other. The first ends of the first and second contact members are positioned within the space defined by the cylindrical insulator in the closed contact state. The contact of at least one of the rotatably supported contact members is positioned outside of the space defined by the cylindrical insulator when the contacts are open.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 16, 2002
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Takao Mitsuhashi, Mitsuru Tsukima, Mitsugu Takahashi, Masahiro Fushimi, Kazunori Fukuya, Shiro Murata, Shinji Yamagata
  • Patent number: 5735743
    Abstract: A game machine having play-by-play announcement includes a monitor, a manipulator, a memory to store data for each of a plurality of vocal sound groups, each vocal sound group expressing a word in connection with the game; a controller operable to produce a new game scene on the monitor in accordance with a game program and an instructive signal generated by the manipulator, and designate data for a vocal sound group suitable to the produced new scene; and a sound generator to generate vocal sounds suitable for the new scene based on the designated data.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: April 7, 1998
    Assignee: Konami Co., Ltd.
    Inventors: Shiro Murata, Koji Toyohara, Naoki Nishikawa, Masahiro Ikariko, Kazuhiko Uehara, Hideto Inoue
  • Patent number: 4945325
    Abstract: A circuit breaker wherein at least a pin sliding surface of a guide hole of a first contact arm, at least a pin sliding surface of a long hole of a second contact arm, and at least a contact surface of a second pin in contact with both the pin sliding surfaces, are treated by low-friction treatment to reduce frictional resistance, and surface-treated to provide surfaces exempt from attachment of molten metal caused by arcing; and furthermore at least the pin sliding surface of the first contact arm and at least the pin sliding surface of the long hole of the second contact arm are hardened to provide both the pin sliding surfaces with greater hardness than the second pin, thereby ensuring smooth movement of the second pin.
    Type: Grant
    Filed: November 17, 1988
    Date of Patent: July 31, 1990
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Haruhisa Toda, Hiroaki Fujihisa, Shiro Murata
  • Patent number: D325568
    Type: Grant
    Filed: November 5, 1990
    Date of Patent: April 21, 1992
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Shiro Murata, Shinji Yamagata, Masakatsu Suzuki
  • Patent number: D325727
    Type: Grant
    Filed: November 5, 1990
    Date of Patent: April 28, 1992
    Assignee: Mitsubishi Denki Kabushiki Kaisha
    Inventors: Shiro Murata, Shinji Yamagata